Published

Self-reported benefits and harms of microdosing with natural psilocybin: preliminary results from a naturalistic study

No abstract availability was recorded for this entry.

Open source BibTeX RIS

Bibliographic context

Journal: Neuroscience Applied
Date: 2026-01-01
Source: OpenAlex
DOI: 10.1016/j.nsa.2026.106942
PubMed: Unavailable

Authors

I. Totomanova E.C.H.M. Haijen P.P.M. Hurks NL Mason JG Ramaekers K.P.C. Kuypers

Watch author

Derived topics and classifications

psilocybin Chronic Pain Microdosing Other

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Self-reported benefits and harms of microdosing with natural psilocybin: preliminary results from a naturalistic study2026-01-01

Related papers

Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic EffectsClinicalTrials.gov · 2026-07-09 A One-Year Observational Follow-up Study of Participants With Major Depressive Disorder Following a Randomized, Double-Blind Single-Dose of Psilocybin or Niacin-ControlClinicalTrials.gov · 2026-05-04 Retrospective Observational Study of Intensity Effects in Psychedelic-assisted TreatmentClinicalTrials.gov · 2025-10-02 Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on AlcoholismClinicalTrials.gov · 2025-09-24 Measurement of Serum Cytokine Levels in Samples Collected as Part of a Clinical Trial of Psilocybin for Treatment-resistant Depression.ClinicalTrials.gov · 2025-09-10 Psilocybin in Patients With Fibromyalgia: EEG-measured Brain Biomarkers of ActionClinicalTrials.gov · 2024-01-19 Multicentre Study To Assess Safety And Efficacy Of Psilocybin In Patients With Treatment-Resistant Depression Following Completion Of COMP 001 And COMP 003 Trials (P-TRD LTFU)ClinicalTrials.gov · 2022-09-22